[Analytical performance verification protocols and performance specifications of platelet-dependent von Willebrand...

Clinical laboratories depend on reliable diagnostic assays to ensure accurate patient care. While general performance verification protocols exist for many tests, specific guidance is lacking for newer assays like platelet-dependent von Willebrand factor (VWF) activity testing. Prior research has shown that standardized verification is essential for consistent results across labs. However, no prior work had resolved the exact criteria for verifying VWF:GPIbM performance. This uncertainty created a need for a structured verification framework. The study aimed to address this gap by evaluating key performance metrics. These metrics include precision, trueness, linearity, and quantitation limits. Without clear verification standards, labs face challenges in ensuring the reliability of this test.

The study aimed to assess the analytical performance of platelet-dependent von Willebrand factor activity testing (VWF:GPIbM) in clinical settings. The goal was to determine whether this test meets the performance criteria outlined in manufacturer guidelines and national standards. The researchers focused on four key aspects: precision, trueness, linearity, and limit of quantitation. These metrics are critical for ensuring the test’s reliability in real-world use. The motivation was to provide a reference for clinical labs to follow when verifying this assay. No prior work had resolved the specific verification criteria for this test. The study sought to close this gap by following CLSI and national guidelines. The findings could help standardize the test across different clinical environments.

The study used the Sysmex CS-5100 instrument and its reagents to evaluate VWF:GPIbM performance. Precision was tested using two quality control samples and three plasma pools over five days. Trueness was assessed by measuring bias in five diluted calibrators. Linearity was verified using ten pooled plasmas across two calibration ranges. The limit of quantitation was tested with two low-activity reference materials. Each verification step followed CLSI and national health standards. The researchers calculated coefficients of variation, regression slopes, and biases. All results were compared against predefined criteria. The approach ensured a comprehensive evaluation of the test’s analytical performance.

Intra-run and inter-run coefficients of variation for precision were 1.0%–2.5% and 1.1%–2.6%, respectively, meeting the manufacturer’s criteria. Trueness verification showed biases ranging from -0.4% to 0.3%, which were within acceptable limits. Linearity verification revealed regression slopes of 1.0217 and 0.9962 for low and normal ranges, with R² values of 0.9935 and 0.9939. The biases for linearity were within -10.1% to 0. The limit of quantitation verification showed biases of -0.4% to 0.3%, meeting CLSI criteria. These results indicate that the test performs within expected ranges. No significant deviations were observed across the tested parameters. The findings support the reliability of the VWF:GPIbM assay in clinical settings.

The study concluded that the VWF:GPIbM assay meets the performance requirements outlined in the package inserts and national standards. The verification criteria for precision, trueness, linearity, and quantitation were all satisfied. These results suggest that the test is suitable for clinical use. The authors propose that these findings can guide clinical laboratories in verifying the assay’s performance. No prior work had resolved the specific verification criteria for this test. The study provides a reference framework for standardizing the test across different labs. The results do not suggest broader generalizations beyond the tested parameters. The authors emphasize the importance of following established verification protocols.